Cargando…

Immunogenicity of measles-rubella vaccine administered under India’s Universal Immunization Programme in the context of measles–rubella elimination goal: A longitudinal study

BACKGROUND & OBJECTIVES: There is a paucity of data regarding immunogenicity of recently introduced measles–rubella (MR) vaccine in Indian children, in which the first dose is administered below one year of age. This study was undertaken to assess the immunogenicity against rubella and measles 4...

Descripción completa

Detalles Bibliográficos
Autores principales: Verma, Santosh Kumar, Shah, Dheeraj, Singh, Aaradhana, Singh, Praveen Kumar, Das, Shukla, Gupta, Piyush
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438412/
https://www.ncbi.nlm.nih.gov/pubmed/37102515
http://dx.doi.org/10.4103/ijmr.IJMR_4113_20
_version_ 1785092785497440256
author Verma, Santosh Kumar
Shah, Dheeraj
Singh, Aaradhana
Singh, Praveen Kumar
Das, Shukla
Gupta, Piyush
author_facet Verma, Santosh Kumar
Shah, Dheeraj
Singh, Aaradhana
Singh, Praveen Kumar
Das, Shukla
Gupta, Piyush
author_sort Verma, Santosh Kumar
collection PubMed
description BACKGROUND & OBJECTIVES: There is a paucity of data regarding immunogenicity of recently introduced measles–rubella (MR) vaccine in Indian children, in which the first dose is administered below one year of age. This study was undertaken to assess the immunogenicity against rubella and measles 4-6 wk after one and two doses of MR vaccine administered under India’s Universal Immunization Programme (UIP). METHODS: In this longitudinal study, 100 consecutive healthy infants (9-12 months) of either gender attending the immunization clinic of a tertiary care government hospital affiliated to a medical college of Delhi for the first dose of routine MR vaccination were enrolled. MR vaccine (0.5 ml, subcutaneous) was administered to the enrolled participants (1(st) dose at 9-12 months and 2(nd) dose at 15-24 months). On each follow up (4-6 wk post-vaccination), 2 ml of venous blood sample was collected to estimate the antibody titres against measles and rubella using quantitative ELISA kits. Seroprotection (>10 IU/ml for measles and >10 WHO U/ml for rubella) and antibody titres were evaluated after each dose. RESULTS: The seroprotection rate against rubella was 97.5 and 100 per cent and against measles was 88.7 per cent and 100 per cent 4-6 wk after the first and second doses, respectively. The mean (standard deviation) titres against rubella and measles increased significantly (P<0.001) after the second dose in comparison to the levels after the first dose by about 100 per cent and 20 per cent, respectively. INTERPRETATION & CONCLUSIONS: MR vaccine administered below one year of age under the UIP resulted in seroprotection against rubella and measles in a large majority of children. Furthermore, its second dose resulted in seroprotection of all children. The current MR vaccination strategy of two doses, out of which the first is to be given to infants below one year of age, appears robust and justifiable among Indian children.
format Online
Article
Text
id pubmed-10438412
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-104384122023-08-19 Immunogenicity of measles-rubella vaccine administered under India’s Universal Immunization Programme in the context of measles–rubella elimination goal: A longitudinal study Verma, Santosh Kumar Shah, Dheeraj Singh, Aaradhana Singh, Praveen Kumar Das, Shukla Gupta, Piyush Indian J Med Res Programme: Original Article BACKGROUND & OBJECTIVES: There is a paucity of data regarding immunogenicity of recently introduced measles–rubella (MR) vaccine in Indian children, in which the first dose is administered below one year of age. This study was undertaken to assess the immunogenicity against rubella and measles 4-6 wk after one and two doses of MR vaccine administered under India’s Universal Immunization Programme (UIP). METHODS: In this longitudinal study, 100 consecutive healthy infants (9-12 months) of either gender attending the immunization clinic of a tertiary care government hospital affiliated to a medical college of Delhi for the first dose of routine MR vaccination were enrolled. MR vaccine (0.5 ml, subcutaneous) was administered to the enrolled participants (1(st) dose at 9-12 months and 2(nd) dose at 15-24 months). On each follow up (4-6 wk post-vaccination), 2 ml of venous blood sample was collected to estimate the antibody titres against measles and rubella using quantitative ELISA kits. Seroprotection (>10 IU/ml for measles and >10 WHO U/ml for rubella) and antibody titres were evaluated after each dose. RESULTS: The seroprotection rate against rubella was 97.5 and 100 per cent and against measles was 88.7 per cent and 100 per cent 4-6 wk after the first and second doses, respectively. The mean (standard deviation) titres against rubella and measles increased significantly (P<0.001) after the second dose in comparison to the levels after the first dose by about 100 per cent and 20 per cent, respectively. INTERPRETATION & CONCLUSIONS: MR vaccine administered below one year of age under the UIP resulted in seroprotection against rubella and measles in a large majority of children. Furthermore, its second dose resulted in seroprotection of all children. The current MR vaccination strategy of two doses, out of which the first is to be given to infants below one year of age, appears robust and justifiable among Indian children. Wolters Kluwer - Medknow 2023-04 2023-05-31 /pmc/articles/PMC10438412/ /pubmed/37102515 http://dx.doi.org/10.4103/ijmr.IJMR_4113_20 Text en Copyright: © 2023 Indian Journal of Medical Research https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Programme: Original Article
Verma, Santosh Kumar
Shah, Dheeraj
Singh, Aaradhana
Singh, Praveen Kumar
Das, Shukla
Gupta, Piyush
Immunogenicity of measles-rubella vaccine administered under India’s Universal Immunization Programme in the context of measles–rubella elimination goal: A longitudinal study
title Immunogenicity of measles-rubella vaccine administered under India’s Universal Immunization Programme in the context of measles–rubella elimination goal: A longitudinal study
title_full Immunogenicity of measles-rubella vaccine administered under India’s Universal Immunization Programme in the context of measles–rubella elimination goal: A longitudinal study
title_fullStr Immunogenicity of measles-rubella vaccine administered under India’s Universal Immunization Programme in the context of measles–rubella elimination goal: A longitudinal study
title_full_unstemmed Immunogenicity of measles-rubella vaccine administered under India’s Universal Immunization Programme in the context of measles–rubella elimination goal: A longitudinal study
title_short Immunogenicity of measles-rubella vaccine administered under India’s Universal Immunization Programme in the context of measles–rubella elimination goal: A longitudinal study
title_sort immunogenicity of measles-rubella vaccine administered under india’s universal immunization programme in the context of measles–rubella elimination goal: a longitudinal study
topic Programme: Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438412/
https://www.ncbi.nlm.nih.gov/pubmed/37102515
http://dx.doi.org/10.4103/ijmr.IJMR_4113_20
work_keys_str_mv AT vermasantoshkumar immunogenicityofmeaslesrubellavaccineadministeredunderindiasuniversalimmunizationprogrammeinthecontextofmeaslesrubellaeliminationgoalalongitudinalstudy
AT shahdheeraj immunogenicityofmeaslesrubellavaccineadministeredunderindiasuniversalimmunizationprogrammeinthecontextofmeaslesrubellaeliminationgoalalongitudinalstudy
AT singhaaradhana immunogenicityofmeaslesrubellavaccineadministeredunderindiasuniversalimmunizationprogrammeinthecontextofmeaslesrubellaeliminationgoalalongitudinalstudy
AT singhpraveenkumar immunogenicityofmeaslesrubellavaccineadministeredunderindiasuniversalimmunizationprogrammeinthecontextofmeaslesrubellaeliminationgoalalongitudinalstudy
AT dasshukla immunogenicityofmeaslesrubellavaccineadministeredunderindiasuniversalimmunizationprogrammeinthecontextofmeaslesrubellaeliminationgoalalongitudinalstudy
AT guptapiyush immunogenicityofmeaslesrubellavaccineadministeredunderindiasuniversalimmunizationprogrammeinthecontextofmeaslesrubellaeliminationgoalalongitudinalstudy